



# Detection of Low Frequency Drug Resistant Mutations in Antiretroviral-Treated HIV-1C Infections

## Citation

Okatch, Harriet, Vladimir Novitsky, and Myron Essex. 2006. Detection of low frequency drug resistant mutations in antiretroviral-treated HIV-1C infections. *Retrovirology* 3(Suppl 1): P47.

## Published Version

doi:10.1186/1742-4690-3-S1-P47

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:4553302>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Poster presentation

## Detection of low frequency drug resistant mutations in antiretroviral-treated HIV-1 C infections

Harriet Okatch\*, Vladimir Novitsky and Myron Essex

Address: Harvard School of Public Health, 651 Huntington Avenue, Boston, Massachusetts, 02135, USA

Email: Harriet Okatch\* - hokatch@hsph.harvard.edu

\* Corresponding author

from 2006 International Meeting of The Institute of Human Virology  
Baltimore, USA. 17–21 November, 2006

Published: 21 December 2006

*Retrovirology* 2006, **3**(Suppl 1):P47 doi:10.1186/1742-4690-3-S1-P47

© 2006 Okatch et al; licensee BioMed Central Ltd.

### Purpose of the Study

The objective of this study is to identify low frequency mutations in HIV-1C that cannot be detected by standard genotyping. We analysed samples from the Tshepo cohort in Botswana. Tshepo is an open-label, unblinded, randomised  $3 \times 2 \times 2$  factorial design study comparing 1) the rate of development and specific types of drug resistance mutational patterns among HIV-1C-infected adults treated with 6 initial HAART regimens; (2) the tolerability and efficacy of these HAART regimens; (3) evaluation of the When to Start HAART question as patients are initiated on HAART in two different baseline CD4+ cell count strata; and (4) comparing the short- and long-term effectiveness of two operational adherence strategies.

### Methods

Methodology involved quantification of the proviral load and multiple PCR with a single copy as a template followed by direct sequencing. Bulk sequencing was also carried out for each patient per time point.

### Summary of Results

Of the patients who had been enrolled in the study for at least one year, had longitudinal samples at every two month visit and had failed the first-line therapy, failed therapy, 30% of them showed no drug resistance mutations prior to the point of virological failure by single genome sequencing. Single genome sequencing revealed drug resistance mutations for the remaining 70% of the patients before virological failure was experienced.

### Conclusion

Single genome sequencing allows for the detection of low frequency mutation below the threshold of 30% for bulk sequencing, allows early detection of these mutations for some samples and in addition can detect mutations otherwise missed by conventional methods of detection